Reducing Environmental Pollution by Antibiotics through Design for Environmental Degradation
Research output: Journal contributions › Journal articles › Research › peer-review
Standard
In: ACS Sustainable Chemistry & Engineering, Vol. 9, No. 28, 19.07.2021, p. 9358–9368.
Research output: Journal contributions › Journal articles › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Reducing Environmental Pollution by Antibiotics through Design for Environmental Degradation
AU - Leder, Christoph
AU - Suk, Morten
AU - Lorenz, Stefanie
AU - Rastogi, Tushar
AU - Pfeifer, Christian
AU - Kietzmann, Manfred
AU - Jonas, Daniel
AU - Buck, Marion
AU - Pahl, Axel
AU - Kümmerer, Klaus
N1 - Financial support from the German Federal Environmental Foundation (Deutsche Bundesstiftung Umwelt; Sustainable Pharmacy 2, Project No. 30389) is gratefully acknowledged. The authors thank Steffi Hinz and Janin Westphal for their excellent technical assistance and Lisa Kessler for helpful technical advice on the algal assay. The authors also acknowledge Multicase Inc. and Leadscope Inc. for kindly providing CASE Ultra and Leadscope QSAR software, respectively. A part of the antimicrobial screening was performed by CO-ADD (The Community for Antimicrobial Drug Discovery), funded by the Wellcome Trust (U.K.) and The University of Queensland (Australia). The molecular structure representations and SMILES codes were generated with Marvin sketch 15.6.8.0 kindly provided by ChemAxon Ltd. (Budapest, Hungary). Publisher Copyright: © 2021 The Authors. Published by American Chemical Society.
PY - 2021/7/19
Y1 - 2021/7/19
N2 - The spread of antibiotic-resistant pathogenic bacteria is an increasing health issue worldwide. A possible origin of antibiotic resistance could be the persistence of antibiotics in the aquatic environment. To tackle this problem, restricted control of application of antibiotics in human and veterinary medicine has been proposed. However, these measures do not prevent the spreadof antibiotic resistance but may delay the process, since antibiotics are still continuously emitted into the environment and many persist there. Derived from ciprofloxacin (CIP), CIP-Hemi, a fluoroquinolone with improved environmental properties, was developed following the benign by design approach and using insilico and in vitro methods. CIP-Hemi was designed to maintain its required metabolic stability (human liver microsomes, intestinal microsomes, blood plasma) and antibiotic activity (MIC in the μg mL−1 range) against the target while transforming into an inactive fragment (CIP-d-CP) and a degradable linker present under acidic conditions, e.g., after excretion or when released into theenvironment. Moreover, CIP-Hemi and CIP-d-CP showed weaker cytotoxic and mutagenic or genotoxic effects compared to the parent compound CIP and therefore underline the feasibility of CIP-Hemi as a viable antibiotic drug candidate, demonstrating benign by design as a promising approach.
AB - The spread of antibiotic-resistant pathogenic bacteria is an increasing health issue worldwide. A possible origin of antibiotic resistance could be the persistence of antibiotics in the aquatic environment. To tackle this problem, restricted control of application of antibiotics in human and veterinary medicine has been proposed. However, these measures do not prevent the spreadof antibiotic resistance but may delay the process, since antibiotics are still continuously emitted into the environment and many persist there. Derived from ciprofloxacin (CIP), CIP-Hemi, a fluoroquinolone with improved environmental properties, was developed following the benign by design approach and using insilico and in vitro methods. CIP-Hemi was designed to maintain its required metabolic stability (human liver microsomes, intestinal microsomes, blood plasma) and antibiotic activity (MIC in the μg mL−1 range) against the target while transforming into an inactive fragment (CIP-d-CP) and a degradable linker present under acidic conditions, e.g., after excretion or when released into theenvironment. Moreover, CIP-Hemi and CIP-d-CP showed weaker cytotoxic and mutagenic or genotoxic effects compared to the parent compound CIP and therefore underline the feasibility of CIP-Hemi as a viable antibiotic drug candidate, demonstrating benign by design as a promising approach.
KW - Chemistry
KW - Antibiotics
KW - Benign by design
KW - Fluoroquinolones
KW - Sustainability Science
KW - Sustainable pharmacy
KW - Green chemistry
UR - http://www.scopus.com/inward/record.url?scp=85111067533&partnerID=8YFLogxK
U2 - 10.1021/acssuschemeng.1c02243
DO - 10.1021/acssuschemeng.1c02243
M3 - Journal articles
VL - 9
SP - 9358
EP - 9368
JO - ACS Sustainable Chemistry & Engineering
JF - ACS Sustainable Chemistry & Engineering
SN - 2168-0485
IS - 28
ER -